Jae-Gahb Park
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jae-Gahb Park has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
Il-Jin Kim
Korean Hereditary Tumor Registry, Cancer Research Institute and Cancer Research Center, Seoul National University, Seoul, Korea
8 shared publicationsHio Chung Kang
Korean Hereditary Tumor Registry|Cancer Research Institute|Cancer Research Center|Seoul National University
6 shared publicationsByong Chul Yoo
Research Institute and Hospital, National Cancer Center, Gyeonggi 411-764, Korea
5 shared publicationsHee Jin Chang
Research Institute and Hospital, National Cancer Center, Gyeonggi 411-764, Korea
4 shared publicationsJa-Lok Ku
Korean Hereditary Tumor Registry, Cancer Research Institute and Cancer Research Center, Seoul National University, Seoul, South Korea
4 shared publicationsYong Shin
4 shared publications
Latest Publications
- 31 March 2006
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 32 (2) , 162-167
Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3cm of the anal verge
- 31 March 2006
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 32 (2) , 162-167
Pre-operative chemo-radiotherapy improves the sphincter preservation rate in patients with rectal cancer located within 3cm of the anal verge
- Open Access
- 11 October 2005
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 27 (3) , 392-404
Oligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K- ras mutations
Various types of human cancers harbor BRAF somatic mutations, leading researchers to seek molecular targets for BRAF inhibitors. A mutually exclusive relationship has been observed between the BRAF- V600E mutation and K- ras mutations, suggesting that the BRAF- V600E mutation may differ from the other BRAF mutant types. Here, we used microarray analysis to examine differences between the BRAF and K- ras mutant colorectal samples and within the BRAF group (V600E versus non-V600E), in the hope that the identified gene sets could form the basis for new target development. Eleven colorectal cancers (CRCs) with BRAF mutations and nine with K- ras mutations were examined by high-density microarray analysis. We also tested whether other significant genetic or clinical status involved in CRC development, such as APC and TP53 mutations, MSI and TNM-Duke's staging, were related with the observed BRAF - or K- ras associated expression profiles. Unsupervised two-way hierarchical clustering and multidimensional scaling revealed that the differentially expressed genes clustered according to the mutation status of BRAF and K- ras , and that samples with the BRAF- V600E and non-V600E mutants could be distinguished from each other by gene profiling. Examination of TNM–Duke's staging, MSI and mutations in APC and TP53 revealed that these significant mutations could not account for the hierarchical clustering results observed in our study. We herein identified distinct gene expression patterns and gene sets that may form the basis for identification of BRAF -targeting molecules or provide researchers with a better understanding of the molecular pathogenesis underlying RAS–RAF signaling.
- 11 October 2005
- Published by Oxford University Press (OUP) in Carcinogenesis
- Vol. 27 (3) , 392-404
Open AccessOligonucleotide microarray analysis of distinct gene expression patterns in colorectal cancer tissues harboring BRAF and K- ras mutations
Various types of human cancers harbor BRAF somatic mutations, leading researchers to seek molecular targets for BRAF inhibitors. A mutually exclusive relationship has been observed between the BRAF- V600E mutation and K- ras mutations, suggesting that the BRAF- V600E mutation may differ from the other BRAF mutant types. Here, we used microarray analysis to examine differences between the BRAF and K- ras mutant colorectal samples and within the BRAF group (V600E versus non-V600E), in the hope that the identified gene sets could form the basis for new target development. Eleven colorectal cancers (CRCs) with BRAF mutations and nine with K- ras mutations were examined by high-density microarray analysis. We also tested whether other significant genetic or clinical status involved in CRC development, such as APC and TP53 mutations, MSI and TNM-Duke's staging, were related with the observed BRAF - or K- ras associated expression profiles. Unsupervised two-way hierarchical clustering and multidimensional scaling revealed that the differentially expressed genes clustered according to the mutation status of BRAF and K- ras , and that samples with the BRAF- V600E and non-V600E mutants could be distinguished from each other by gene profiling. Examination of TNM–Duke's staging, MSI and mutations in APC and TP53 revealed that these significant mutations could not account for the hierarchical clustering results observed in our study. We herein identified distinct gene expression patterns and gene sets that may form the basis for identification of BRAF -targeting molecules or provide researchers with a better understanding of the molecular pathogenesis underlying RAS–RAF signaling.
- 22 April 2005
- Published by Elsevier in Human Pathology
- Vol. 36 (4) , 364-371
Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma☆
- 22 April 2005
- Published by Elsevier in Human Pathology
- Vol. 36 (4) , 364-371
Bax, a predictive marker for therapeutic response to preoperative chemoradiotherapy in patients with rectal carcinoma☆
- Open Access
- 10 January 2005
- Published by Hindawi Limited in Human Mutation
- Vol. 25 (2) , 224
Erratum: Germline mutations in MLH1 , MSH2 and MSH6 in Korean hereditary non‐polyposis colorectal cancer families
The original article to which this Erratum refers was published in Human Mutation 24:351 Human Mutation(2004) 24(4) 351 In the original published version of this article, the authors gave inconsistent data. First, the nucleotide change for Family SNU-H18 was correctly cited in Table 1 as “c.632_633insT,” but was incorrectly listed as “c.622_623insT” in the Results section. Please note that the correct nucleotide change for this family is “c.632_633insT.” Second, in the data for Family SNU-H2007 in Table 1, the nucleotide change given was incorrect as “MLH1/IVS16;” and should correctly read “MLH1/IVS15.” The authors apologize for these errors.
- 10 January 2005
- Published by Hindawi Limited in Human Mutation
- Vol. 25 (2) , 224
Open AccessErratum: Germline mutations in MLH1 , MSH2 and MSH6 in Korean hereditary non‐polyposis colorectal cancer families
The original article to which this Erratum refers was published in Human Mutation 24:351 Human Mutation(2004) 24(4) 351 In the original published version of this article, the authors gave inconsistent data. First, the nucleotide change for Family SNU-H18 was correctly cited in Table 1 as “c.632_633insT,” but was incorrectly listed as “c.622_623insT” in the Results section. Please note that the correct nucleotide change for this family is “c.632_633insT.” Second, in the data for Family SNU-H2007 in Table 1, the nucleotide change given was incorrect as “MLH1/IVS16;” and should correctly read “MLH1/IVS15.” The authors apologize for these errors.
- Open Access
- 1 January 2005
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 37 (6) , 325-331
Nationwide Cancer Incidence in Korea, 1999~2001; First Result Using the National Cancer Incidence Database
Shin HR, et al. Cancer Res Treat. 2005 Dec;37(6):325-331. http://dx.doi.org/10.4143/crt.2005.37.6.325
- 1 January 2005
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 37 (6) , 325-331
Open AccessNationwide Cancer Incidence in Korea, 1999~2001; First Result Using the National Cancer Incidence Database
Shin HR, et al. Cancer Res Treat. 2005 Dec;37(6):325-331. http://dx.doi.org/10.4143/crt.2005.37.6.325
- Open Access
- 1 January 2005
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 11 (26) , 4124-4126
Familial gastric cancers with Li-Fraumeni Syndrome: A case repast
We report a case of the rare solid-pseudopapillary tumor of the pancreas. In contrast to other.
- 1 January 2005
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 11 (26) , 4124-4126
Open AccessFamilial gastric cancers with Li-Fraumeni Syndrome: A case repast
We report a case of the rare solid-pseudopapillary tumor of the pancreas. In contrast to other.
- Open Access
- 1 January 2005
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 37 (1) , 20-23
Single Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia
Sohn DK, et al. Cancer Res Treat. 2005 Feb;37(1):20-23. http://dx.doi.org/10.4143/crt.2005.37.1.20
- 1 January 2005
- Published by Korean Cancer Association in Cancer Research and Treatment
- Vol. 37 (1) , 20-23
Open AccessSingle Immunochemical Fecal Occult Blood Test for Detection of Colorectal Neoplasia
Sohn DK, et al. Cancer Res Treat. 2005 Feb;37(1):20-23. http://dx.doi.org/10.4143/crt.2005.37.1.20
- 24 September 2004
- Published by Springer Nature in Human Genetics
- Vol. 115 (6) , 498-503
Mutational analysis of OGG1, MYH, MTH1 in FAP, HNPCC and sporadic colorectal cancer patients: R154H OGG1 polymorphism is associated with sporadic colorectal cancer patients
MYH, OGG1 and MTH1 are members of base excision repair (BER) families, and MYH germline mutations were recently identified in patients with multiple adenomas or familial adenomatous polyposis (FAP). A total of 20 APC-negative Korean FAP patients were analyzed for OGG1, MYH and MTH1 germline mutations. A total of 19 hereditary nonpolyposis colorectal cancer (HNPCC), 86 suspected HNPCC, and 246 sporadic colorectal cancer cases were investigated for OGG1 and MYH mutations. A total of 14 R154H OGG1 polymorphisms were identified in hereditary, sporadic colorectal cancers, and normal controls. For the case-control analysis of OGG1 R154H, a total of 625 hereditary or sporadic colorectal cancer patients and 527 normal controls were screened. R154H was a rare polymorphism associated with sporadic colorectal cancer patents (OR: 3.586, P= 0.053). R154H does not segregate with cancer phenotypes. Upon examining the possibility of recessive inheritance of R154H, we could not identify any complementary mutations in OGG1, MYH or MTH1. Samples with R154H were further screened for mutations of K-ras, β-catenin, APC, p53, BRAF and the microsatellite instability (MSI) status. Eight somatic mutations were identified in these genes and G:C to T:A transversion mutations were not dominant in samples harboring R154H. This result raises the possibility that OGG1 R154H may function as a low/moderate-penetrance modifier for colorectal cancer development.
- 24 September 2004
- Published by Springer Nature in Human Genetics
- Vol. 115 (6) , 498-503
Mutational analysis of OGG1, MYH, MTH1 in FAP, HNPCC and sporadic colorectal cancer patients: R154H OGG1 polymorphism is associated with sporadic colorectal cancer patients
MYH, OGG1 and MTH1 are members of base excision repair (BER) families, and MYH germline mutations were recently identified in patients with multiple adenomas or familial adenomatous polyposis (FAP). A total of 20 APC-negative Korean FAP patients were analyzed for OGG1, MYH and MTH1 germline mutations. A total of 19 hereditary nonpolyposis colorectal cancer (HNPCC), 86 suspected HNPCC, and 246 sporadic colorectal cancer cases were investigated for OGG1 and MYH mutations. A total of 14 R154H OGG1 polymorphisms were identified in hereditary, sporadic colorectal cancers, and normal controls. For the case-control analysis of OGG1 R154H, a total of 625 hereditary or sporadic colorectal cancer patients and 527 normal controls were screened. R154H was a rare polymorphism associated with sporadic colorectal cancer patents (OR: 3.586, P= 0.053). R154H does not segregate with cancer phenotypes. Upon examining the possibility of recessive inheritance of R154H, we could not identify any complementary mutations in OGG1, MYH or MTH1. Samples with R154H were further screened for mutations of K-ras, β-catenin, APC, p53, BRAF and the microsatellite instability (MSI) status. Eight somatic mutations were identified in these genes and G:C to T:A transversion mutations were not dominant in samples harboring R154H. This result raises the possibility that OGG1 R154H may function as a low/moderate-penetrance modifier for colorectal cancer development.
- 10 September 2004
- Published by Springer Nature in Journal of Human Genetics
- Vol. 49 (11) , 591-595
A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome
Journal of Human Genetics, official journal of the Japan Society of Human Genetics, publishes original articles and reviews on all aspects of human genetics, including medical genetics and genomics
- 10 September 2004
- Published by Springer Nature in Journal of Human Genetics
- Vol. 49 (11) , 591-595
A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome
Journal of Human Genetics, official journal of the Japan Society of Human Genetics, publishes original articles and reviews on all aspects of human genetics, including medical genetics and genomics
- Open Access
- 30 August 2004
- Published by Hindawi Limited in Human Mutation
- Vol. 24 (4) , 351
Germline mutations inMLH1,MSH2 andMSH6 in Korean hereditary non-polyposis colorectal cancer families
Hereditary non-polyposis colorectal cancer (HNPCC), the most common hereditary colon cancer syndrome, is a dominant disorder caused by germline defects in mismatch repair (MMR) genes. Identification of MMR gene mutations can have direct clinical implications in counseling and management of HNPCC families. We screened 44 HNPCC and 97 suspected HNPCC Korean families for germline mutations in three MMR genes: MLH1, MSH2 and MSH6.We identified twelve novel mutations: nine in MLH1(c.632_633insT, c.808_811delACTT, c.845C>G, c.1625A>C, c.1730+1delG, c.1907T>C, c.1918C>T, c.2104-2A>G and c.2170T>A), two in MSH2 (c.1886A>G, c.1316_1318delCCT) and one in MSH6 (c.3488A>T). In addition, two statically significant cSNPs in MLH1: c.1128T>C ( p=0.008 in HNPCC and p=0.037 in early-onset CRC) and c.2168C>A ( pMLH1, was a founder mutation inherited from a common Korean ancestor.
- 30 August 2004
- Published by Hindawi Limited in Human Mutation
- Vol. 24 (4) , 351
Open AccessGermline mutations inMLH1,MSH2 andMSH6 in Korean hereditary non-polyposis colorectal cancer families
Hereditary non-polyposis colorectal cancer (HNPCC), the most common hereditary colon cancer syndrome, is a dominant disorder caused by germline defects in mismatch repair (MMR) genes. Identification of MMR gene mutations can have direct clinical implications in counseling and management of HNPCC families. We screened 44 HNPCC and 97 suspected HNPCC Korean families for germline mutations in three MMR genes: MLH1, MSH2 and MSH6.We identified twelve novel mutations: nine in MLH1(c.632_633insT, c.808_811delACTT, c.845C>G, c.1625A>C, c.1730+1delG, c.1907T>C, c.1918C>T, c.2104-2A>G and c.2170T>A), two in MSH2 (c.1886A>G, c.1316_1318delCCT) and one in MSH6 (c.3488A>T). In addition, two statically significant cSNPs in MLH1: c.1128T>C ( p=0.008 in HNPCC and p=0.037 in early-onset CRC) and c.2168C>A ( pMLH1, was a founder mutation inherited from a common Korean ancestor.